PTGX

Dopo l'orario di chiusura: 46.20 0.01 +0.02%

Protagonist Therapeutics Inc (PTGX)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Protagonist Therapeutics Inc

(510) 474-0170

7707 GATEWAY BLVD., SUITE 140, NEWARK, CA

Prossima data di guadagno

Ultimi documenti SEC

PTGX's Discussions on Twitter

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-05-25	Ripresa	Jefferies	Buy
2022-08-25	Iniziato	JMP Securities	Mkt Outperform
2022-02-11	Iniziato	BTIG Research	Buy
2021-10-12	Aggiornamento	JP Morgan	Neutral → Overweight
2021-10-11	Aggiornamento	Northland Capital	Market Perform → Outperform
2021-09-20	Downgrade	JP Morgan	Overweight → Neutral
2021-05-24	Iniziato	JMP Securities	Mkt Outperform
2021-05-24	Iniziato	Northland Capital	Outperform
2021-01-06	Iniziato	JP Morgan	Overweight
2020-12-16	Iniziato	Piper Sandler	Overweight
2020-09-18	Reiterato	H.C. Wainwright	Buy
2020-07-15	Iniziato	Jefferies	Buy
2020-05-18	Reiterato	H.C. Wainwright	Buy
2019-07-08	Iniziato	H.C. Wainwright	Buy
2019-05-09	Aggiornamento	Stifel	Hold → Buy
2018-12-06	Iniziato	Nomura	Buy
2018-01-29	Iniziato	Stifel	Buy
2017-07-21	Iniziato	BTIG Research	Buy

Mostra tutto

Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie

Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari

Protagonist Therapeutics Inc Azioni (PTGX) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Ali Asif	Chief Financial Officer	Sep 11 '24	Sale	44.49	14,203	631,872	34,960
Waddill William D.	Director	Sep 10 '24	Option Exercise	12.88	8,000	103,040	20,000
Waddill William D.	Director	Sep 10 '24	Sale	45.00	8,000	360,000	12,000

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie

Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High at $47.75 - MarketBeat

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells $631,891.47 in Stock - Defense World

Principal Financial Group Inc. Sells 4,341 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Protagonist therapeutics CFO sells over $630k in company stock - Investing.com

HC Wainwright Increases Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $50.00 - Defense World

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CFO Sells $631,891.47 in Stock - MarketBeat

PTGX Shares Experience Surge in Value - Knox Daily

Protagonist Therapeutics director Waddill sells $360,000 in stock - Investing.com India

Protagonist Therapeutics director Waddill sells $360,000 in stock - Investing.com

Truist Securities Initiates Coverage of Protagonist Therapeutics (PTGX) with Buy Recommendation - MSN

HC Wainwright Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $50.00 - MarketBeat

TD Asset Management Inc Grows Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon Corp - Defense World

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of “Buy” from Analysts - Defense World

TD Asset Management Inc Boosts Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Protagonist Therapeutics Inc (PTGX) expanding its growth trajectory ahead - SETE News

Objective long/short (PTGX) Report - Stock Traders Daily

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines - AOL

Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines - Yahoo Finance

Great Lakes Advisors LLC Decreases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Protagonist Therapeutics stock hits 52-week high at $43.79 By Investing.com - Investing.com Australia

Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated by Analysts at Truist Financial - Defense World

Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High at $44.05 - MarketBeat

Protagonist Therapeutics stock hits 52-week high at $43.79 - Investing.com

Protagonist Therapeutics stock hits 52-week high at $43.79 By Investing.com - Investing.com Canada

Truist initiates coverage on Protagonist Therapeutics shares with Buy rating By Investing.com - Investing.com Canada

Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated at Truist Financial - MarketBeat

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - Simply Wall St

Candriam S.C.A. Sells 86,182 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Cannon Global Investment Management LLC Purchases New Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Check Out Protagonist Therapeutics Inc (PTGX)’s Trade Data Rather Than the Analysts’ Views - SETE News

Metric Analysis: Protagonist Therapeutics Inc (PTGX)’s Key Ratios in the Limelight - The Dwinnex

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 - StockTitan

Protagonist Therapeutics Inc [PTGX] Stock sold by Insider Waddill William D. for $0.32 million - Knox Daily

Protagonist Therapeutics stock hits 52-week high at $42.72 By Investing.com - Investing.com Australia

Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High at $43.31 - MarketBeat

Keeping an Eye on Protagonist Therapeutics Inc (PTGX) After Insider Trading Activity - Knox Daily

Protagonist Therapeutics stock hits 52-week high at $42.72 - Investing.com

Protagonist Therapeutics, Inc. announced that it expects to receive $18.04 million in funding. - Marketscreener.com

Protagonist Therapeutics, Inc. announced that it has received $18 million in funding from Pharmstandard International S.A., Johnson & Johnson InnovationJJDC, Inc., Lilly Ventures Management Company, LLC, Starfish Ventures Pty Ltd - Marketscreener.com

Taking the lead: Protagonist Therapeutics Inc (PTGX) - SETE News

SG Americas Securities LLC Buys Shares of 10,951 Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Hennion & Walsh Asset Management Inc. - Defense World

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Protagonist Therapeutics : Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera - Marketscreener.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of “Buy” by Analysts - Defense World

Long Term Trading Analysis for (PTGX) - Stock Traders Daily

Protagonist Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences - Marketscreener.com

Protagonist Therapeutics : to Present at the BMO 2019 Prescription for Success Healthcare Conference - Marketscreener.com

California State Teachers Retirement System Sells 3,153 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Protagonist Therapeutics Inc Azioni (PTGX) insider trading

Simile a PTGX